{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:19:10Z","timestamp":1767986350296,"version":"3.49.0"},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,12,15]]},"DOI":"10.2169\/internalmedicine.1056-18","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T22:36:43Z","timestamp":1535063803000},"page":"3545-3549","source":"Crossref","is-referenced-by-count":10,"title":["Hepatocellular Carcinoma in a Patient with Hereditary Hemorrhagic Telangiectasia"],"prefix":"10.2169","volume":"57","author":[{"given":"Kazuhiko","family":"Morii","sequence":"first","affiliation":[{"name":"Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riku","family":"Uematsu","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeharu","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Okushin","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Nishiwaki","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Japanese Red Cross Society Himeji Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyohei","family":"Kai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Japanese Red Cross Society Himeji Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiso","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Japanese Red Cross Society Himeji Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 19: 140-148, 2002.","DOI":"10.1002\/humu.10026"},{"key":"2","unstructured":"2. Azuma H. Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia. J Med Invest 47: 81-90, 2000."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Scardapane A, Ficco M, Sabb\u00e0 C, et al. Hepatic nodular regenerative lesions in patients with hereditary haemorrhagic telangiectasia: computed tomography and magnetic resonance findings. Radiol Med 118: 1-13, 2013.","DOI":"10.1007\/s11547-012-0789-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48: 73-87, 2011.","DOI":"10.1136\/jmg.2009.069013"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Singh S, Swanson KL, Hathcock MA, et al. Identifying the presence of clinically significant hepatic involvement in hereditary haemorrhagic telangiectasia using a simple clinical scoring index. J Hepatol 61: 124-131, 2014.","DOI":"10.1016\/j.jhep.2014.02.028"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Brenard R, Chapaux X, Deltenre P, et al. Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients. Eur J Gastroenterol Hepatol 22: 1253-1259, 2010.","DOI":"10.1097\/MEG.0b013e32833ac4a1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Jameson CF. Primary hepatocellular carcinoma in hereditary haemorrhagic telangiectasia: a case report and literature review. Histopathology 15: 550-552, 1989.","DOI":"10.1111\/j.1365-2559.1989.tb01618.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hosman AE, Devlin HL, Silva BM, et al. Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis 8: 195, 2013.","DOI":"10.1186\/1750-1172-8-195"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Krings T, Ozanne A, Chng SM, et al. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology 47: 711-720, 2005.","DOI":"10.1007\/s00234-005-1390-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sabb\u00e0 C, Pasculli G, Suppressa P, et al. Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM 99: 327-334, 2006.","DOI":"10.1093\/qjmed\/hcl037"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shovlin CL, Sodhi V, McCarthy A, et al. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services. BJOG 115: 1108-1115, 2008.","DOI":"10.1111\/j.1471-0528.2008.01786.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. de Gussem EM, Edwards CP, Hosman AE, et al. Life expectancy of parents with Hereditary Haemorrhagic Telangiectasia. Orphanet J Rare Dis 11: 46, 2016.","DOI":"10.1186\/s13023-016-0427-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Duarte CW, Murray K, Lucas FL, et al. Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. Cancer Epidemiol Biomarkers Prev 23: 117-125, 2014.","DOI":"10.1158\/1055-9965.EPI-13-0665"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Massagu\u00e9 J. TGFbeta in Cancer. Cell 134: 215-230, 2008.","DOI":"10.1016\/j.cell.2008.07.001"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mitchell D, Pobre EG, Mulivor AW, et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 9: 379-388, 2010.","DOI":"10.1158\/1535-7163.MCT-09-0650"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rosen LS, Hurwitz HI, Wong MK, et al. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 18: 4820-4829, 2012.","DOI":"10.1158\/1078-0432.CCR-12-0098"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lakshman M, Huang X, Ananthanarayanan V, et al. Endoglin suppresses human prostate cancer metastasis. Clin Exp Metastasis 28: 39-53, 2011.","DOI":"10.1007\/s10585-010-9356-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Romero D, O'Neill C, Terzic A, et al. Endoglin regulates cancer-stromal cell interactions in prostate tumors. Cancer Res 71: 3482-3493, 2011.","DOI":"10.1158\/0008-5472.CAN-10-2665"},{"key":"19","unstructured":"19. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship. Am J Gastroenterol 91: 879-884, 1996."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Langrehr JM, Pfitzmann R, Hermann M, et al. Hepatocellular carcinoma in association with hepatic focal nodular hyperplasia. Acta Radiol 47: 340-344, 2006.","DOI":"10.1080\/02841850600570474"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Chen TC, Chou TB, Ng KF, et al. Hepatocellular carcinoma associated with focal nodular hyperplasia. Report of a case with clonal analysis. Virchows Arch 438: 408-411, 2001.","DOI":"10.1007\/s004280000348"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kellner U, Jacobsen A, Kellner A, et al. Comparative genomic hybridization. Synchronous occurrence of focal nodular hyperplasia and hepatocellular carcinoma in the same liver is not based on common chromosomal aberrations. Am J Clin Pathol 119: 265-271, 2003.","DOI":"10.1309\/EF69VNDLVPWVE4QV"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mancuso A. The ischemic liver cirrhosis theory and its clinical implications. Med Hypotheses 94: 4-6, 2016.","DOI":"10.1016\/j.mehy.2016.06.008"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2: 16018, 2016.","DOI":"10.1038\/nrdp.2016.18"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.","DOI":"10.1038\/nrc704"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bogaerts E, Heindryckx F, Vandewynckel YP, et al. The roles of transforming growth factor-\u03b2, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours. Int J Oncol 44: 1015-1022, 2014.","DOI":"10.3892\/ijo.2014.2286"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Gaujoux S, Bucau M, Ronot M, et al. Liver resection in patients with hepatic hereditary hemorrhagic telangiectasia. Dig Surg 30: 410-414, 2013.","DOI":"10.1159\/000351446"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Mitchell A, Adams LA, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 14: 210-213, 2008.","DOI":"10.1002\/lt.21417"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307: 948-955, 2012.","DOI":"10.1001\/jama.2012.250"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/24\/57_1056-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T04:45:50Z","timestamp":1544849150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/24\/57_1056-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,15]]},"references-count":29,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1056-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,15]]}}}